Nebulized Recombinant Human Tissue Factor Pathway Inhibitor Attenuates Coagulation and Exerts Modest Anti-inflammatory Effects in Rat Models of Lung Injury

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 30, Issue 2, 2017, Pages 91-99

  Van Den Boogaard, Florry E ^a   Hofstra, Jorrit J ^a   Brands, Xanthe ^a   Levi, Marcel M ^a   Roelofs, Joris J T H ^a   Zaat, Sebastiaan A J ^a   Van'T Veer, Cornelis ^a   Van Der Poll, Tom ^a   Schultz, Marcus J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

coagulation; endotoxemia; lung; pneumonia; Pseudomonas aeruginosa; tissue factor pathway inhibitor

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; LIPOPOLYSACCHARIDE; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BLOOD CLOTTING; BRONCHOALVEOLAR LAVAGE FLUID; CONTROLLED STUDY; FIBRINOLYSIS; LUNG INJURY; MALE; NEBULIZER; NONHUMAN; PLASMA; PSEUDOMONAS AERUGINOSA; RAT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUMAN; INFLAMMATION; PATHOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BLOOD COAGULATION; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FIBRINOLYSIS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LIPOPROTEINS; LUNG INJURY; MALE; PSEUDOMONAS AERUGINOSA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 85017104720     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2016.1317     Document Type: Article

References (35)

1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, and Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149: 818-824.
2. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, and Seeger W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000;161:454-462.
3. Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, Spek CA, Reitsma PH, van der Zee JS, Levi M, and van der Poll T: Local activation of the tissue factorfactor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med. 2006;34:1725-1730.
4. Wygrecka M, Jablonska E, Guenther A, Preissner KT, and Markart P: Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost. 2008;99:494-501.
5. Schultz MJ, Haitsma JJ, Zhang H, and Slutsky AS: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia-A review. Crit Care Med. 2006;34:871-877.
6. Crawley JT, and Lane DA: The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28:233-242.
7. Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, and Ware LB: Intra-Alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol. 2008;294: L874-L881.
8. de Moerloose P, De Benedetti E, Nicod L, Vifian C, and Reber G: Procoagulant activity in bronchoalveolar fluids: No relationship with tissue factor pathway inhibitor activity. Thromb Res. 1992;65:507-518.
9. Choi G, Vlaar AP, Schouten M, Vant Veer C, van der Poll T, Levi M, and Schultz MJ: Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J. 2007;30:423-428.
10. Miller DL, Welty-Wolf K, Carraway MS, Ezban M, Ghio A, Suliman H, and Piantadosi CA: Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol. 2002;26:650-658.
11. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, Idell S, and Piantadosi CA: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med. 2001;164: 1988-1996.
12. Enkhbaatar P, Okajima K, Murakami K, Uchiba M, Okabe H, Okabe K, and Yamaguchi Y: Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med. 2000;162:1752-1759.
13. van den Boogaard FE, Hofstra JJ, vant Veer C, Levi MM, Roelofs JJ, van der Poll T, and Schultz MJ: Feasibility and safety of local treatment with recombinant human tissue factor pathway inhibitor in a rat model of Streptococcus pneumoniae pneumonia. PLoS One. 2015;10:e0127261.
14. DixonB, SchultzMJ, Hofstra JJ, CampbellDJ, and Santamaria JD: Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care. 2010;14:445.
15. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, and Campbell DJ: Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: A randomized controlled trial. Crit Care. 2010;14: R180.
16. Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, and van der Poll T: Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol. 2002;282:L285-L290.
17. Choi G, Hofstra JJ, Roelofs JJ, Rijneveld AW, Bresser P, van der Zee JS, Florquin S, van der Poll T, Levi M, and Schultz MJ: Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med. 2008;36:204-210.
18. Hofstra JJ, Cornet AD, de Rooy BF, Vlaar AP, van der Poll T, Levi M, Zaat SA, and Schultz MJ: Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care. 2009;13:R145.
19. Sandset PM, Abildgaard U, and Pettersen M:Asensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res. 1987;47:389-400.
20. van den Boogaard FE, BrandsX, Schultz MJ, LeviM, Roelofs JJ, vant Veer C, and van der Poll T: Recombinant human tissue factor pathway inhibitor exerts anticoagulant, antiinflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost. 2011;9:122-132.
21. Levi M, and van der Poll T: Inflammation and coagulation. Crit Care Med. 2010;38:S26-S34.
22. van der Poll T: Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care. 2008;12 Suppl 6:S3.
23. Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun TC, Creasey AA, and Hinshaw LB: Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock. 1994;44:126-137.
24. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJ, and van der Poll T: Tissue factor pathway inhibitor dosedependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000;95:1124-1129.
25. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, van Deventer SJ, Hack CE, ten Cate JW, and Rosenberg RD: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-Tissue factor antibody in chimpanzees. J Clin Invest. 1994;93:114-120.
26. Moons AH, Peters RJ, Cate H, Bauer KA, Vlasuk GP, Buller HR, and Levi M: Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost. 2002;88:627-631.
27. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De DC, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, and Creasey AA: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA. 2003;290:238-247.
28. Cornet AD, Hofstra JJ, Vlaar AP, van den Boogaard FE, Roelofs JJ, van der Poll T, Levi M, Groeneveld AB, and Schultz MJ: Nebulized anticoagulants limit coagulopathy but not inflammation in Pseudomonas aeruginosa-induced pneumonia in rats. Shock. 2011;36: 417-423.
29. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJ, and van der Poll T: Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis. 2001;183:1815-1818.
30. Papareddy P, Kalle M, Sorensen OE, Malmsten M, Morgelin M, and Schmidtchen A: The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog. 2013;9:e1003803.
31. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB, Jr., and Hinshaw LB: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850-2860.
32. Welty-Wolf KE, Carraway MS, Idell S, Ortel TL, Ezban M, and Piantadosi CA: Tissue factor in experimental acute lung injury. Semin Hematol. 2001;38:35-38.
33. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, and Opal S: Recombinant tissue factor pathway inhibitor in severe community-Acquired pneumonia: A randomized trial. Am J Respir Crit Care Med. 2011;183:1561-1568.
34. Honeybourne D: Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med. 1997;3:170-174.
35. Tuinman PR, Dixon B, Levi M, Juffermans NP, and Schultz MJ: Nebulized anticoagulants for acute lung injury-A systematic review of preclinical and clinical investigations. Crit Care. 2012;16:R70.